Home > Oncology > ASCO 2020 > Lung Cancer > Thoracic cancers versus COVID-19

Thoracic cancers versus COVID-19

In a global registry, 428 thoracic cancer patients infected with COVID-19 have been followed up, and the data are concerning. 169 have recovered, 119 have ongoing COVID-19 infection, but 141 have died.

Prof. Leora Horn (Vanderbilt Ingram Cancer Center, USA) presented the results of the Thoracic Cancers International COVID-19 Collaboration (TERAVOLT) registry [1]. "Patients with thoracic malignancies are considered high-risk given their age, pre-existing comorbidities, smoking, and pre-existing lung damage in addition to therapies administered to treat their illness. We launched a global consortium to collect data on patients with thoracic malignancies diagnosed with COVID-19 infection to understand the impact on this patient population," she said.

Among registered deaths, 79.4% were attributed to COVID-19 and 10.6% to the patients' progressive cancer. Another 8.5% died of a combination of cancer and COVID-19. Just 8.3% of the patients were admitted ...

please login to read the entire article:

You need to register to read the entire article, please do so now.

Posted on